Coherus BioSciences (CHRS) Tops Q4 EPS by 20c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.35 +9.76%
EPS Growth %: +39.4%
Financial Fact:
Basic net income/(loss) per share: 0.15
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +39.4%
Financial Fact:
Basic net income/(loss) per share: 0.15
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.60), $0.20 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $45.35 million versus the consensus estimate of $48.41 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Lumentum shares rise on analyst upgrades, AI demand outlook
- UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
